Q-omics provides the consensus-scored INTS14 profile across patient tissues and cancer cell-line models. INTS14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, INTS14 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, INTS14 protein abundance shows 35,078 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where INTS14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INTS14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INTS14 survival associations across molecular data types. INTS14 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INTS14 RNA expression–survival associations across cancer types. High INTS14 expression shows unfavorable associations in ACC, UVM, PAAD, LGG and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for INTS14 RNA expression.
This table summarizes INTS14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for INTS14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INTS14 shows higher tumor expression in HNSC, BLCA, STAD, COAD, LIHC and LUAD. The HNSC box plot shows higher INTS14 RNA expression in tumor versus normal tissue (log2 FC = +0.869, t-test p < 0.001).
This table shows molecular features associated with INTS14 in patient tissues and cancer cell lines. In patient samples, INTS14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, INTS14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
